R. Peck

发表

Phase I and pharmacokinetic study of the novel MDR1 and MRP1 inhibitor biricodar administered alone and in combination with doxorubicin.

F. Atkins, M. Harding, M. Hawkins, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Q‐TWiST analysis of ixabepilone in combination with capecitabine on quality of life in patients with metastatic breast cancer

G. Hortobagyi, D. Revicki, P. Conte, 2012, Cancer.

Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas.

Suzanne F. Jones, P. Sabbatini, H. Burris, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety of repeated administrations of ixabepilone given as a 3-hour infusion every other week in combination with irinotecan in patients with advanced malignancies.

E. Raymond, J. Soria, S. Faivre, 2008, European journal of cancer.

Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.

Bing-he Xu, J. Sparano, A. Manikhas, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Targeting KIT on innate immune cells to enhance the antitumor activity of checkpoint inhibitors.

J. Eder, R. Gedrich, T. Lavallee, 2016, Immunotherapy.

Apoptotic pathways of epothilone BMS 310705.

F. Lee, T. Mekhail, R. Ganapathi, 2003, Gynecologic oncology.

Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment.

H. Gómez, Bing-he Xu, M. Campone, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses.

E. Gehan, J. Marshall, J. Schlom, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

CCR5 governs DNA damage and breast cancer stem cell expansion

Sandra, H. Rui, G. Prendergast, 2017 .

Combination Therapy With Ixabepilone Plus Capecitabine Is Effective in ER/PR/HER2-Negative Breast Cancer Resistant to Anthracyclines and Taxanes

M. Piontek, H. Roché, M. Verrill, 2008 .

Clinical activity of the novel epothilone B analog, ixabepilone, in triple negative breast cancer (BC) patients

X. Pivot, A. Llombart-Cussac, Miguel Martín, 2008 .

Ixabepilone-associated peripheral neuropathy: data from across the phase II and III clinical trials

E. Perez, G. Hortobagyi, J. Sparano, 2012, Supportive Care in Cancer.

Ixabepilone plus capecitabine in advanced breast cancer patients with early relapse after adjuvant anthracyclines and taxanes: a pooled subset analysis of two phase III studies.

M. Campone, J. Jassem, L. Vahdat, 2012, Breast.

Ixabepilone plus capecitabine in metastatic breast cancer patients with reduced performance status previously treated with anthracyclines and taxanes: a pooled analysis by performance status of efficacy and safety data from 2 phase III studies

E. Perez, G. Hortobagyi, Bing-he Xu, 2011, Breast Cancer Research and Treatment.

Ixabepilone plus capecitabine improves overall survival in symptomatic patients with metastatic breast cancer previously treated with anthracycline and taxane in 2 large phase III studies.

E. Perez, G. Hortobagyi, Bing-he Xu, 2009 .

Phase III trial of ixabepilone plus capecitabine compared to capecitabine alone in patients with metastatic breast cancer (MBC) previously treated or resistant to an anthracycline and resistant to taxanes

H. Gómez, J. Jassem, H. Chung, 2007 .

Phase I dose escalation study of weekly ixabepilone, an epothilone analog, in patients with advanced solid tumors who have failed standard therapy

Suzanne F. Jones, M. Piccart, H. Burris, 2009, Cancer Chemotherapy and Pharmacology.

Abstract 44: The discovery of ARV-471, an orally bioavailable estrogen receptor degrading PROTAC for the treatment of patients with breast cancer

J. Flanagan, C. Crews, Y. Qian, 2021, Experimental and Molecular Therapeutics.

First-in-human phase I study of ARV-110, an androgen receptor (AR) PROTAC degrader in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) following enzalutamide (ENZ) and/or abiraterone (ABI).

I. Taylor, H. Burris, D. Petrylak, 2020 .

The development of immunomodulatory monoclonal antibodies as a new therapeutic modality for cancer: the Bristol-Myers Squibb experience.

A. Korman, N. Lonberg, D. Feltquate, 2015, Pharmacology & therapeutics.

Phase I/II study of ixabepilone plus capecitabine in anthracycline-pretreated/resistant and taxane-resistant metastatic breast cancer.

J. Gralow, C. Bunnell, L. Schwartzberg, 2008, Clinical breast cancer.

Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non small-cell lung cancer whose tumors have failed first-line platinum-based chemotherapy.

M. Socinski, M. Edelman, J. Vansteenkiste, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine.

E. Perez, G. Hortobagyi, L. Bosserman, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy.

J. Sparano, L. Mauriac, D. Lebwohl, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abstract 43: Discovery of ARV-110, a first in class androgen receptor degrading PROTAC for the treatment of men with metastatic castration resistant prostate cancer

C. Crews, T. Neklesa, I. Taylor, 2021, Experimental and Molecular Therapeutics.

Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes

G. Hortobagyi, H. Gómez, Bing-he Xu, 2010, Breast Cancer Research and Treatment.

Ixabepilone plus capecitabine vs capecitabine in patients with metastatic breast cancer receiving ixabepilone in the first line setting: a pooled analysis from two phase III studies.

M. Campone, J. Jassem, L. Vahdat, 2009 .

O-3 Randomized phase II study of the novel tubulin targetin agent, BMS-247550 (Epothilone B analogue) in the treatment of non-small cell lung cancer (NSCLC) in patients (pts) who have failed first line platinum containing therapy

M. Edelman, L. Paz-Ares, J. Vansteenkiste, 2003 .

Ixabepilone given weekly in patients with advanced malignancies: Final efficacy and safety results of a phase I trial.

H. Burris, R. Peck, N. Dickson, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I study of ixabepilone given every other week in combination with irinotecan in patients with advanced malignancies.

E. Raymond, J. Armand, S. Faivre, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Final results from a phase I trial of ixabepilone in patients with advanced malignancies and lymphoma.

H. Burris, C. Aghajanian, M. Cohen, 2006, Journal of Clinical Oncology.

Safety, pharmacokinetics (PK), pharmacodynamics (Pd), and antitumor activity in a phase 1b study evaluating anti-ErbB3 antibody KTN3379 in adults with advanced tumors alone and with targeted therapies.

P. LoRusso, J. Eder, G. Falchook, 2016 .

Maintenance of clinical efficacy following dose reduction of ixabepilone plus capecitabine (Cape) in patients (pts) with anthracycline (A) and taxane (T) pretreated (pretx) metastatic breast cancer (MBC): A retrospective analysis of pooled data from two phase III clinical studies (046/048).

V. Valero, L. Bosserman, J. Sparano, 2010 .